Evidence map›Paper›PMID 35056910›Full record

ArticlePharmaceutics2021

Quantitative Analysis of the Phase Transition Mechanism Underpinning the Systemic Self-Assembly of a Mechanopharmaceutical Device.

Steven Dunne, Andrew R Willmer, Rosemary Swanson, Deepak Almeida, Nicole C Ammerman, Kathleen A Stringer, Edmund V Capparelli, Gus R Rosania

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Molecular design of a pathogen activated, self-assembling mechanopharmaceutical device.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Steven DunneDepartment of Chemistry, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0001-5877-5464
Andrew R WillmerDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0002-5966-0068
Rosemary SwansonJohns Hopkins Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Deepak AlmeidaJohns Hopkins Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Nicole C AmmermanJohns Hopkins Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0001-9359-9144
Kathleen A StringerDepartment of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0003-0238-7774
Edmund V CapparelliDepartment of Pediatrics, Skaggs School of Pharmacy and Pharmaceutical Science, University of California, San Diego, CA 92093, USA.
Gus R RosaniaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA.ORCID 0000-0003-3214-5565
University of Michigan · USJohns Hopkins University · USUniversity of California San Diego · US

Funding

Translational Metabolomics in Critical CareR35GM136312 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KATHLEEN A STRINGER · 2020 to 2026
$2.8M
L-Carnitine As A Metabolic Biomarker of Drug Toxicity RiskR01GM127787 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ROSANIA, GUS R · 2019 to 2022
$2.0M
NIGMS NIH HHS R01 GM127787NIGMS NIH HHS R01GM127787NIGMS NIH HHS R35 GM136312NIGMS NIH HHS R35GM136312
6 · The paper itself

Abstract

Clofazimine (CFZ) is a poorly soluble, weakly basic, small molecule antibiotic clinically used to treat leprosy and is now in clinical trials as a treatment for multidrug resistant tuberculosis and COVID-19. CFZ exhibits complex, context-dependent pharmacokinetics that are characterized by an increasing half-life in long term treatment regimens. The systemic pharmacokinetics of CFZ have been previously represented by a nonlinear, 2-compartment model incorporating an expanding volume of distribution. This expansion reflects the soluble-to-insoluble phase transition that the drug undergoes as it precipitates out and accumulates within macrophages disseminated throughout the organism. Using mice as a model organism, we studied the mechanistic underpinnings of this increasing half-life and how the systemic pharmacokinetics of CFZ are altered with continued dosing. To this end,

Indexed as

drug deliverydrug targetingmodeling and simulationpharmacokineticssmall moleculestuberculosis

Identifiers

PMID35056910
PMCPMC8780429
OpenAlexW4200339661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.